NCT01474083 - A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes | Biotech Hunter

Enrollment

248

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

GK1-399 (formerly TTP399)

Treatment A: GK1-399 200 mg. Oral administration, twice per day.

DRUG

GK1-399 (formerly TTP399)

Treatment B: GK1-399 800 mg. Oral administration, once per day.

DRUG

GK1-399 (formerly TTP399)

Treatment C: GK1-399 800 mg. Oral administration, twice per day.

DRUG

Placebo

Dose-matched placebo. Oral administration.

Trial Locations (11)

Forest Investigative Site 007, New York

Forest Investigative Site 002, DeLand

Forest Investigative Site 001, Miami

Forest Investigative site 011, Saint Paul

Forest Investigative Site 005, Springfield

Forest Investigative Site 010, Overland Park

Forest Investigative Site 009, Little Rock

Forest Investigative Site 004, San Antonio

Forest Investigative Site 006, Chula Vista

Forest Investigative Site 003, Neptune City

Forest Investigative Site 008, Willingboro